| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative … RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ... The lancet oncology 16 (1), 25-35, 2015 | 2173 | 2015 |
| Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative … C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ... Journal of clinical oncology 33 (9), 983-991, 2015 | 1129 | 2015 |
| The humoral immune system has a key prognostic impact in node-negative breast cancer M Schmidt, D Böhm, C von Törne, E Steiner, A Puhl, H Pilch, HA Lehr, ... Cancer research 68 (13), 5405-5413, 2008 | 905 | 2008 |
| Trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study G von Minckwitz, A du Bois, M Schmidt, N Maass, T Cufer, FE de Jongh, ... Journal of Clinical Oncology 27 (12), 1999-2006, 2009 | 869 | 2009 |
| A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors M Filipits, M Rudas, R Jakesz, P Dubsky, F Fitzal, CF Singer, O Dietze, ... Clinical Cancer Research 17 (18), 6012-6020, 2011 | 795 | 2011 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 703 | 2020 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 676 | 2017 |
| Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen W Schroth, MP Goetz, U Hamann, PA Fasching, M Schmidt, S Winter, ... Jama 302 (13), 1429-1436, 2009 | 656 | 2009 |
| Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters G Fritz, C Brachetti, F Bahlmann, M Schmidt, B Kaina British journal of cancer 87 (6), 635-644, 2002 | 517 | 2002 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 499 | 2021 |
| Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials C Denkert, F Seither, A Schneeweiss, T Link, JU Blohmer, M Just, ... The Lancet Oncology 22 (8), 1151-1161, 2021 | 394 | 2021 |
| The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients P Dubsky, JC Brase, R Jakesz, M Rudas, CF Singer, R Greil, O Dietze, ... British journal of cancer 109 (12), 2959-2964, 2013 | 387 | 2013 |
| A clinically relevant gene signature in triple negative and basal-like breast cancer A Rody, T Karn, C Liedtke, L Pusztai, E Ruckhaeberle, L Hanker, R Gaetje, ... Breast cancer research 13, 1-12, 2011 | 382 | 2011 |
| A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors M Schmidt, B Hellwig, S Hammad, A Othman, M Lohr, Z Chen, D Boehm, ... Clinical cancer research 18 (9), 2695-2703, 2012 | 267 | 2012 |
| Loss of circadian clock gene expression is associated with tumor progression in breast cancer C Cadenas, L Van De Sandt, K Edlund, M Lohr, B Hellwig, R Marchan, ... Cell Cycle 13 (20), 3282-3291, 2014 | 265 | 2014 |
| Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer C Cadenas, D Franckenstein, M Schmidt, M Gehrmann, M Hermes, ... Breast cancer research 12, 1-15, 2010 | 240 | 2010 |
| EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer P Dubsky, M Filipits, R Jakesz, M Rudas, CF Singer, R Greil, O Dietze, ... Annals of oncology 24 (3), 640-647, 2013 | 239 | 2013 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 235 | 2022 |
| Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision … N Harbeck, M Schmitt, C Meisner, C Friedel, M Untch, M Schmidt, ... European journal of cancer 49 (8), 1825-1835, 2013 | 227 | 2013 |
| The impact of treatment for genital cancer on quality of life and body image—results of a prospective longitudinal 10-year study S Hawighorst-Knapstein, C Fusshoeller, C Franz, K Trautmann, ... Gynecologic oncology 94 (2), 398-403, 2004 | 216 | 2004 |
Volkmar MüllerUniversity Medical Center Hamburg Eppendorf在 uke.de 的电子邮件经过验证
